# Pizarra — PT-pseudo_394e0b8dbeeb (task 1)

---

# Ronda 1

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_394e0b8dbeeb
Task: 1

Encounter: Urology - outpatient on 04 Jan 2025.
Referrer: Dr. E. Mulder (GP).
Type: Re-evaluation - prior negative biopsy.

Clinical data (read-only — values loaded from the record):
  - 71-year-old male
  - PSA: 9.2 ng/mL
  - mpMRI — PI-RADS score: 4 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.17 ng/mL²
  - PSA velocity: 1.1 ng/mL/yr
  - Prior PSA: 10.1 ng/mL
  - Prostate volume: 53.0 mL
  - Months since last PSA: 3
  - DRE findings: Nodus (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Negative (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.78939086 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Hypercholesterolaemia, Coronary artery disease, Obesity (BMI >30), Benign prostatic hyperplasia
  - Problem list / PMHx: Hypercholesterolaemia, Coronary artery disease, Obesity (BMI >30), Benign prostatic hyperplasia
  - Current medication: atorvastatin, simvastatin, rosuvastatin, aspirin 80 mg, metoprolol, tamsulosin
  - Allergies: NKA
  - Additional notes: PSA 9.2 ng/mL. PI-RADS 4. PSAD 0.17. Prostate volume 53 mL. DRE nodus. csPCa 0.79.

Vitals: weight 93 kg, height 164 cm, BMI 34.6, BP 114/71 mmHg, HR 70 bpm. Smoking: Current smoker (45 pack-yr).

Chief complaint: Elevated PSA progression alongside a newly identified PI-RADS 4 lesion on multiparametric MRI has necessitated specialist re-assessment.

History: Mr X, a 71-year-old harbour pilot (semi-retired), entered initial evaluation in early 2023 following an incidental PSA elevation. Lower urinary tract symptoms remain mild and are currently managed with tamsulosin, yielding an IPSS score of 7. He reports no haematuria or acute urinary retention. Cardiovascular comorbidities encompass coronary artery disease and hypercholesterolaemia, managed through a regimen of atorvastatin, simvastatin, rosuvastatin, aspirin 80 mg, and metoprolol. He is a Current smoker (45 pack-yr) but maintains physical activity by cycling roughly 30 kilometres three times weekly. Obesity (BMI >30) is present. He remains married and lives with his partner. An adult daughter handles his medical correspondence upon request. Aside from the urological investigations, he experiences stable bilateral knee discomfort stemming from years of deck work and recently visited a podiatrist for routine nail care. No systemic symptoms or unexplained weight loss are reported.

Physical examination: DRE — prostate: asymmetrically enlarged, firm texture, discrete nodule palpable in the right mid-gland. General examination remains unremarkable, with stable vital signs and no evidence of palpable lymphadenopathy or abdominal masses.

Patient info: harbour pilot (semi-retired); Married; Lives with partner.
Next of kin: Adult son (primary contact).

Lifestyle: alcohol 8 units / week; exercise Cycling 3x/week, ~30 km; IPSS score: 7/35 (mild LUTS).

Recent other appointments: Podiatry — routine foot care.
Admin: Daughter manages communication; CC on letters with patient consent.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status in the panel above is all the pathology information on record.]

## [2] STATISTICAL PRIOR (classifier)

**EXPERT-PRIOR** — *statistical expert; bagged classifier over the structured panel, trained on the labelled cohort, out-of-fold honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: BIOPSY
  p(biopsy = yes) = 0.80 +/- 0.07   (95% CI 0.66-0.94)

Two different uncertainties, reported separately because they mean different things:
  - epistemic  dp = 0.07  — the error bar on this number. It is the spread
    across bootstrap members: how much the answer would move with a different training sample.
  - aleatoric  H  = 0.72 of 1.00 — how mixed the outcome was among
    patients this model cannot tell apart. High H means the disagreement is in the data, not in
    the model, and more labelled cases would not fix it.

TIER 'firm': p +/- 1.96*dp does not cross the 0.5 threshold. Treat it as a strong prior that should only be overturned by explicit contradicting evidence. Measured accuracy in this tier on the labelled cohort: 1.0 over 28 cases.

Model: RF over the A-core variable set, chosen by the ablation study, not assumed.
Out-of-fold performance on the 91 labelled cases (5x5 StratifiedKFold, out-of-fold):
  accuracy 0.714 (majority-class baseline 0.615), AUC 0.789, F1(yes) 0.78.
Variables it could not read for this patient: none.

It has read ONLY the structured panel and the parsed record. It has not reasoned about the
prose of the mpMRI report, and it does not know what this patient's management plan is.

## [3] GUIDELINE CRITERION FOR THIS SITUATION

**EXPERT-PROTOCOL** — *protocol expert; applies the guideline criterion for this patient's clinical situation*

CLINICAL SITUATION: prior negative biopsy.

CRITERION VERDICT: BIOPSY.

The criterion: Re-biopsy (targeted) when the mpMRI shows a PI-RADS 4-5 lesion; do not repeat a negative biopsy for a PI-RADS 3 or lower picture that has not changed.

In the labelled cohort this criterion matched the reading urologist in 16 of the 18 cases with a prior negative biopsy.

Track record of this criterion on the labelled cohort: 16 of 18 cases matched the reading urologist. Departing from it needs a specific finding from a retrieved document, named explicitly - not a restatement of the panel numbers it already used.

Like the statistical prior, this expert has read ONLY the visible panel. It has not seen the
mpMRI prose, the PSA trajectory, the previous notes or the laboratory panel.

## [4] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [5] AGENDA (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

AGENDA FOR ROUND 1. These are the documents this case needs opened, and the question each one must answer. Open these and nothing else unless a named question requires it.

  - radiology_report (get_mri_report) -> Does the mpMRI report provide sufficient detail on the PI-RADS 4 lesion to warrant re-biopsy?
  - psa_trend (get_psa_trend) -> Does the PSA trend provide evidence of significant progression or instability?
  - previous_notes (get_previous_notes) -> What was the prior management plan and what was agreed upon with the patient regarding the prior negative biopsy?

This case hinges on whether the PI-RADS 4 finding on the MRI, combined with the PSA trend and prior management context, overrides the statistical prior and guideline criterion to recommend a biopsy.

## [6] GAPS AND DOUBTS (round 1)

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical prior only considered the structured panel, failing to weigh the clinical context of the PI-RADS 4 finding against the rising PSA velocity (1.1 ng/mL/yr) and the prior negative biopsy status.
The prior did not account for the specific PSA density (0.17 ng/mL²) or the specific PI-RADS 4 score, which are key features that might contradict the general positive suggestion.
The prior did not incorporate the specific guideline criterion that mandates re-biopsy based on a PI-RADS 4 lesion following a prior negative biopsy.

WHY THE SUGGESTION COULD BE WRONG
The prior suggested BIOPSY with a high probability (0.80), but the guideline criterion suggests a specific path based on the PI-RADS 4 finding. If the PI-RADS 4 finding is deemed sufficient by the guideline, the prior's high probability might be based on insufficient data integration.
The prior's high probability might be inflated by the high csPCa predicted probability (0.789) without adequately factoring in the prior negative biopsy status, which changes the question from "does he have cancer" to "is the lesion confirmed/progressed."
The prior's uncertainty (epistemic dp = 0.07) suggests the model is uncertain about the correct path, which is precisely what is needed to investigate.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology report - Does the mpMRI report provide sufficient detail on the PI-RADS 4 lesion to warrant re-biopsy?
psa_trend - Does the PSA trend provide evidence of significant progression or instability?
previous_notes - What was the prior management plan and what was agreed upon with the patient regarding the prior negative biopsy?
laboratory_results - What is the full laboratory panel, specifically looking for PSA density context?

GUIDELINE ANCHOR
The guideline states that a repeat biopsy is mandated when the mpMRI shows a PI-RADS 4-5 lesion, and this criterion has a track record of matching the reading urologist in 16 of 18 cases with a prior negative biopsy.

## [7] EVIDENCE REPORT (round 1)

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
{"case_id": "PT-pseudo_394e0b8dbeeb", "radiology_report": "PI-RADS 4 lesion in the right mid-gland peripheral zone. Prostate volume 53.0 mL yielding a PSA density of 0.17 ng/mL/mL. csPCa predicted probability 0.78939086."}
get_psa_trend
[{"date": "Apr 2023", "val": 7.0}, {"date": "Nov 2023", "val": 7.9}, {"date": "Jun 2024", "val": 6.5}, {"date": "Jan 2025", "val": 9.2}]
get_previous_notes
[{"date": "15 Jan 2023", "author": "Dr. E. Mulder (GP)", "text": "Initial laboratory workup in April 2023 flagged a PSA elevation of 6.1 ng/mL. The individual noted mild urinary hesitancy, though acute retention and haematuria were absent. Because of his age and the first elevation, clinicians arranged a follow-up PSA test six months later and initiated a urology referral for baseline evaluation."}, {"date": "06 Sep 2024", "author": "Dr. E. Mulder (GP)", "text": "Subsequent laboratory data collected in June 2024 showed a further rise to 10.1 ng/mL, prompting a repeat multiparametric MRI that located a suspicious focus. In light of the earlier negative biopsy, the steady upward PSA trend, and the present imaging results, specialist input was requested. The case was forwarded to the urology outpatient department for clinical re-assessment and to review targeted sampling options."}]

NOT RETRIEVED
get_lab_results
The full laboratory panel was not retrieved because the moderator's agenda did not explicitly require it, and no information from the retrieved documents raised a specific question requiring its retrieval.

WHAT THE EVIDENCE SUPPORTS
FOR sampling this patient now:
- MRI report: PI-RADS 4 lesion in the right mid-gland peripheral zone.
- PSA trend: Significant progression from 6.5 ng/mL (Jun 2024) to 9.2 ng/mL (Jan 2025).
- Previous notes: The case was forwarded to urology for re-assessment following a prior negative biopsy and a rising PSA trend.

AGAINST sampling this patient now:
- Previous notes: Prior biopsy was negative.

WHERE THIS LEANS
The combination of a PI-RADS 4 lesion, rising PSA velocity, and the prior negative biopsy strongly supports the guideline criterion for re-biopsy.
LEAN: biopsy

[Opened in this round: radiology_report, psa_trend, previous_notes. Open on the board so far: radiology_report, psa_trend, previous_notes.]

## [8] CLOSING CHECK (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

THE CONFERENCE MAY CLOSE.

Positions on the table: prior=yes, protocol=yes, evidence=yes.
Consensus: yes — unanimous among those who took a position.
Agenda: requested ['radiology_report', 'psa_trend', 'previous_notes']; opened ['radiology_report', 'psa_trend', 'previous_notes']; still missing nothing.

The retrieved evidence (PI-RADS 4 lesion, significant PSA progression, and prior negative biopsy) strongly supports the guideline criterion for re-biopsy. The record is sufficient to proceed to the final decision.

The chair decides on the record as it stands.

## [9] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: clear)

The decision to recommend biopsy is supported by convergence across all inputs. The guideline criterion mandates re-biopsy for a PI-RADS 4 lesion, which was retrieved, combined with the rising PSA trend (from 6.5 to 9.2 ng/mL) and the prior negative biopsy status. The statistical prior also suggested biopsy, and the PI-RADS 4 score was decisive in this context. The evidence strongly supports proceeding with targeted sampling.

Variables that carried weight: bx=decisive, age=important, psa=important, vol=noted, psad=important, pirads=decisive, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes
